Can Mounjaro, Zepbound & Foundayo Keep Fueling LLY's Growth Story?

Eli Lilly's GLP-1 portfolio is driving growth in 2026, with Mounjaro, Zepbound and Foundayo gaining traction across obesity, diabetes and related markets.